Targeting IDH mutations for the treatment of AML

Targeting IDH mutations for the treatment of AML

VJHemOnc

1 year
127 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains the mechanisms of isocitrate dehydrogenase (IDH) mutations and their effect on myeloid differentiation, ultimately leading to the phenotype of acute myeloid leukemia (AML). Targeting the IDH mutation, using IDH inhibitors, may lead to the reversal of this differentiation blockade. Dr Stein discusses the IDH2 inhibitor enasidenib, which received FDA approval last year for the treatment of relapsed and refractory AML, and the IDH1 inhibitor ivosidenib, which is currently under FDA review. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Up Next Autoplay
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Acute Lymphoblastic Leukemia
14 Views
kidneycancer 9 hours
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
1 Views
UVA Cancer Center 10 hours
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
2 Views
Cancer-News 13 hours
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
10 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
4 Views
CURC 1 day
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 1 day
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 1 day
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 1 day
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 1 day